Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO.
Info & Links
CEO
Samuel Kintz
Headquarters
6200 Lookout Road Boulder, CO 80301, UNITED STATES
Enliven Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
1.11B
Enterprise Value
1.01B
Enterprise Value/EBITDA(ttm)
-9.25
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
3.61
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-31.84%
Return on Invested Capital(ttm)
-31.95%
Return on Assets(ttm)
-30.09%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-108.91M
Net Income Available to Common(ttm)
-94.83M
Diluted EPS(ttm)
-1.92
Share Statistics
Beta (5Y Monthly)
0.83
52-Week Change
-28.70%
S&P 500 52-Week Change
16.39%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
49.07M
Dividend Yield
0.00%
Float4
36.36M
% Held by Insiders
25.90%
% Held by Institutions
95.08%
Balance Sheet
Total Cash(mrq)
289.56M
Total Cash Per Share(mrq)
5.90
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
21.06%
Quick Ratio(mrq)
21.06%
Book Value Per Share(mrq)
5.88
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.48
Free Cash Flow(ytd)
-24.15M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.